RxDoctor Payments Data

Samuel Cho, MD

Gastroenterology · Flushing, NYNPI 1801839501

Payments from drug & device makers

$6,164in general payments, 2019–2025

Across 129 payments — averaging $47.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$1K
  • Braintree Laboratories, Inc.$1K
  • AbbVie$671
  • Cerapedics Inc.$631
  • Gilead$260
  • Amarin Pharma, Inc.$243
  • plus $2K from 17 others

What the payments were for

  • Grants$1,00016%
  • Travel & lodging$1,58926%
  • Food & beverage$3,53557%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,164 in reported general payments places this provider in the 65th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$93,908
Medicare patients
164
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase67$82,553
VemlidyTenofovir Alafenamide22$52,735
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates466$30,753
ZenpepLipase/Protease/Amylase16$20,100
LinzessLinaclotide31$16,707
Mesalamine39$9,300
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate16$8,658
Mesalamine ErMesalamine44$3,313
Omeprazole305$2,641
Hydrocortisone12$2,105
Sucralfate11$1,890
Dexlansoprazole DrDexlansoprazole11$1,872
Tenofovir Disoproxil Fumarate21$1,849
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl148$1,831
SuprepSodium, Potassium,mag Sulfates14$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$671$99,26098 claims
GileadVemlidy$260$52,73522 claims
Aimmune Therapeutics, Inc.Zenpep$19$20,10016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →